Ernexa Therapeutics Inc. short interest in 2023
In 2023, Ernexa Therapeutics Inc.'s disclosed short interest ran from 1.11% of shares outstanding on 13 Jan 2023 to 2.48% on 29 Dec 2023, a change of +1.37 percentage points. The year's high was 2.48% on 31 May 2023 and its low 0.75% on 15 Feb 2023, averaging 1.79% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 47.00 days on 13 Oct 2023. Full history: Ernexa Therapeutics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.11% (13 Jan 2023)
- End of year
- 2.48% (29 Dec 2023)
- Change
- +1.37 pp
- High
- 2.48% (31 May 2023)
- Low
- 0.75% (15 Feb 2023)
- Average
- 1.79%
- Highest days to cover
- 47.00 (13 Oct 2023)
- SEC filings marked
- 5
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.11% | 1.02 | |
| 31 Jan 2023 | 0.91% | 2.10 | |
| 15 Feb 2023 | 0.75% | 1.00 | |
| 28 Feb 2023 | 1.05% | 2.22 | |
| 15 Mar 2023 | 1.33% | 6.90 | |
| 31 Mar 2023 | 1.22% | 15.50 | 10-K filed, results (8-K) |
| 14 Apr 2023 | 1.59% | 11.86 | |
| 28 Apr 2023 | 1.84% | 17.04 | |
| 15 May 2023 | 1.51% | 6.55 | 10-Q filed |
| 31 May 2023 | 2.48% | 1.43 | |
| 15 Jun 2023 | 1.93% | 5.90 | |
| 30 Jun 2023 | 2.05% | 10.75 | |
| 14 Jul 2023 | 2.02% | 7.93 | |
| 31 Jul 2023 | 1.99% | 5.42 | |
| 15 Aug 2023 | 1.81% | 9.17 | 10-Q filed |
| 31 Aug 2023 | 1.99% | 12.95 | |
| 15 Sep 2023 | 2.41% | 7.18 | |
| 29 Sep 2023 | 2.02% | 17.64 | |
| 13 Oct 2023 | 2.05% | 47.00 | |
| 31 Oct 2023 | 2.19% | 8.01 | |
| 15 Nov 2023 | 2.28% | 6.14 | 10-Q filed |
| 30 Nov 2023 | 2.12% | 4.19 | |
| 29 Dec 2023 | 2.48% | 4.53 |
See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.